Skip to main content
. 2017 Oct 18;3(10):e1701797. doi: 10.1126/sciadv.1701797

Fig. 3. Assessment of the full LEPS platform featuring CPS encapsulation across 20 serotypes and surface localization of GlpO and PncO.

Fig. 3

(A) IgG titers against PncO, GlpO, and encapsulated CPS from indicated S. pneumoniae serotypes in mice serum after vaccination. (B) Mouse challenge protection data comparison between PCV13, PPSV23, and the complete LEPS system (LEPS20/PncO + GlpO) using a colonization model and in vivo perturbation with influenza A administration to prompt pneumonia development. Survival is indicated across vaccination options when challenged with the indicated serotypes, which are, in part, covered by PCV13 (19F) and PPSV23 (19F and 11A) and fully covered by LEPS20/PncO + GlpO. (C) Bacterial counts from the nasopharynx surface (NP), nasopharynx wash (lavage), lungs, and blood 1 and 5 days after IAV administration when challenged with 11A (left) and 35C (right) serotypes.